Schering-Plough China To Acquire Shanghai Schering-Plough
This article was originally published in PharmAsia News
The equity transfer of Shanghai Schering-Plough's 45 percent has gone into the final stages of price quotation. According to sources at share-owner Shanghai Pharmaceutical (Group) which is selling its stake, the quotation system still maintains its list price of 66.33 million yuan. Except for original shareholder Schering-Plough China, no other company has submitted application of acceptance; thus, there will be no surprises if Schering-Plough China takes over Shanghai Schering-Plough. So far the equity transaction has started and will be completed at the beginning of July. Shanghai Schering-Plough will then become a wholly-owned subsidiary of a foreign pharmaceutical firm. (Click here for more - Chinese Language)
You may also be interested in...
Merged company plans expansion throughout China and the Asia-Pacific region.
Schering-Plough Splits With Chinese Joint Venture Partners To Complete Globe-spanning Merger With Organon
BEIJING - Schering-Plough has split with its two joint venture partners in Shanghai in order to complete a worldwide merger with the Netherlands-headquartered Organon BioSciences, according to Schering-Plough executives in the U.S. and China
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.